Takeda
Takeda’s $5.2B Ariad Deal Yields Label Expansion for Iclusig in Rare Leukemia
Takeda, Ariad, $5.2B deal, Iclusig, Label expansion, Rare form of leukemia
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s